Meridian Wealth Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Meridian Wealth Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	–	–	88
2021 Q1	$0	Buy	+4	New	+$176	﹤0.01%	1319

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Meridian Wealth Partners's ACAD Position: Q2 2021 in Review

Meridian Wealth Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 4 shares.

Meridian Wealth Partners first reported a position in ACAD in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Meridian Wealth Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Meridian Wealth Partners sold 4 Acadia Pharmaceuticals shares in Q2 2021.
Meridian Wealth Partners first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Meridian Wealth Partners's Acadia Pharmaceuticals position peaked at $0 in Q1 2021.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.